Document is current

Article History

Received: 27 January 2025

Accepted: 14 April 2025

First Online: 15 May 2025

Declarations

:

: John R. Ingram is a consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, Insmed, Kymera Therapeutics, Novartis, UCB Pharma, UNION therapeutics, and Viela Bio. He is immediate-past Editor-in-Chief of the BJD and receives an authorship honorarium for two UpToDate HS chapters. He is co-copyright holder of HiSQOL and Investigator and Patient Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. Jacek C. Szepietowski has served as an advisor for AbbVie, LEO Pharma, Novartis, Pierre Fabre, Menlo Therapeutics, and Trevi; he has received speaker honoraria from AbbVie, Janssen-Cilag, LEO Pharma, Novartis, Sanofi-Genzyme, Sun Pharma and Eli Lilly, and he has received clinical trial funding from AbbVie, Almirall, Amgen, Galapagos, Holm, Incyte Corporation, InfraRX, Janssen-Cilag, Menlo Therapeutics, Merck, Novartis, Pfizer, Regeneron, Trevi and UCB. Lukasz Matusiak has been an advisory board/consultant for AbbVie, Leo Pharma, Novartis, Pierre Fabre; a speaker for AbbVie, Janssen, Leo-Pharma, Novartis, Pierre Fabre, Valeant; Involved in clinical trials with AbbVie, Almirall, Amgen, Bio-Thera, BMS, Celltrion, Galderma, Galapagos, Incyte, InfraRX, Janssen, Kiniksa, Medimmune, Menlo Therapeutics, Novartis, Pfizer, Regeneron, UCB, Teva and Trevi. JSK has been an advisory board/consultant for AbbVie, Bayer, ChemoCentryx, Incyte, Janssen, Novartis, Moonlake and UCB, and has received speaker fees from AbbVie, Janssen and UCB. Georgios Kokolakis reports consulting fees from Bayer; payment or honoraria from AbbVie, Abbott, Actelion Pharmaceuticals, Amgen, Basilea Pharmaceutica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Parexel, Pfizer and UCB; support for attending meetings or travel from AbbVie, Abbott, Amgen, Basilea Pharmaceutica, Celgene, Janssen-Cilag, LEO Pharma, MSD, Novartis, Pfizer, Sanofi and UCB, and served on a Data Safety Monitoring Board or Advisory Board for AbbVie, Abbott, Amgen, Basilea, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, LEO Pharma, Eli Lilly, Novartis, Takeda and UCB. Magdalena B. Wozniak is an employee and stockholder at Novartis Ireland Limited, Dublin, Ireland. Christine-Elke Ortmann, Angela Llobet Martinez, Nicolas Thomas and Ivette Alarcon are employees of Novartis Pharma AG, Basel, Switzerland. Shoba Ravichandran was an employee of Novartis Pharmaceuticals, East Hanover, New Jersey, USA at the time of the study, and is now retired. Christelle C. Pieterse is an employee of Syneos Health fully contracted to Novartis. Maryam S. Alam has been the principal investigator for clinical trials funded by Novartis, Arcutis Biotherapeutics, Galderma Laboratories, Eli Lilly, AbbVie, Pfizer, Concert pharmaceutical, Dermira pharmaceutical, UCB, Incyte, Boehringer Ingelheim, Amgen, Evelo Sciences, Leo Pharma, Bristol-Myers- Squibb, Dice Therapeutics, Kiniska Pharmaceuticals, Zai Lab co., Sanofi and Bausch Health. MSA has been on the advisory board for the following companies Amgen, AbbVie, Sanofi, Novartis, Incyte, Boehringer Ingelheim, UCB, Arcutis, Bristol-Myers- Squibb and Bausch Health. Dimitrios Ioannides has collaborated in educational and scientific activities and has taken part in advisory services of AbbVie, Amgen, Eli Lilly, Genesis, Janssen, Novartis, Pfizer, Sanofi and UCB. Alexa B. Kimball reports grants from AbbVie, Admirx, Anapyts Bio, Aristea, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Moonlake, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Bio and UCB, and fellowship funding from AbbVie and Janssen paid to her institution; royalties from BIDMC; honoraria or consulting fees from AbbVie, Alumis, Avalos, Bayer, Boehringer Ingelheim, Eli Lilly, Evoimmune, Innovaderm, Janssen, Novartis, Moonlake, Pfizer, Priovant, Sanofi, Sonoma Bio, Target RWE, UCB and Union Therapeutics; serving on advisory boards for Target RWE; serving as an advisory council member to the National Institute of Health Director; and serves on the board of directors of Almirall.

: The study protocol and all amendments for the SUNSHINE and SUNRISE trials were reviewed by the independent ethics committee or institutional review board for each participating centre. The study was done according to The International Conference on Harmonisation Guidelines for Good Clinical Practice that have their origin in the Declaration of Helsinki. Written informed consent was obtained from each patient during the screening visit and before any study-specific procedure was done.